Afrezza vs ORMD-0801
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin · full Type 2 Diabetes pipeline
Afrezza
Marketed by MannKind Corporation and partners
NCT00332488 · Phase 3 · completed
The trial randomized 528 participants across three treatment groups and used an active comparator, but it was open-label rather than blinded and its primary endpoint was the surrogate measure HbA1c. The primary comparison was not met: HbA1c decreased by 0.70% with inhaled insulin plus metformin versus 0.78% with metformin plus secretagogue (p=0.420).
Reported efficacy
Change in HbA1c from baseline to week 26 (non-inferiority vs rapid-acting insulin analog, margin 0.4%): HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. (missed)
Result source: NCT04974528
ORMD-0801
Developed by Lifeward Ltd. and partners
NCT04606576 · Phase 3 · terminated
This is a large, randomized, fully blinded, placebo-controlled trial using blood sugar control (A1C), the standard disease-defining measure for diabetes, as its primary endpoint, a well-designed setup for showing a real treatment effect. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: April 2027 · NCT06731075 (registry estimate)
Reported efficacy
Mean change from baseline in A1C (Baseline and 26 Weeks): Phase 3 ORA-D-013-1 (710 patients): ORMD-0801 vs placebo, primary endpoint (mean change from baseline in HbA1c at 26 weeks) not met; secondary endpoint (fasting plasma glucose change) also not met. (missed)
Result source: NCT04606576
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Afrezza | ORMD-0801 |
|---|---|---|
| HbA1c, change | -0.7% vs -0.8%vs Metformin & SecretagoguesNCT003324883 other results
| -0.6% vs -0.1%−0.5 vs placeboNCT034679328 other results
|
| Body weight, change (kg) | —Not posted · NCT00539890 | —Trial running · NCT06731075 |
| HbA1c below 7% | —Not posted · NCT00539890 | —Trial running · NCT06731075 |
| Fasting plasma glucose, change | —Not posted · NCT00539890 | —Trial running · NCT06731075 |
| 3-point MACE (% with event) | —Not posted · NCT00539890 | —Trial running · NCT06731075 |
HbA1c, change
- Afrezza
- -0.7% vs -0.8%vs Metformin & SecretagoguesNCT00332488
3 other results
- 0.1% vs -0.8% NCT00332488
- -1.8% vs -1.2% NCT00332488
- -1.7% vs -1.2% NCT00332488
- ORMD-0801
- -0.6% vs -0.1%−0.5 vs placeboNCT03467932
8 other results
- -0.6% vs -0.1% NCT03467932
- -0.5% vs -0.1% NCT03467932
- 0.1% vs -0.1% NCT03467932
- -0.9% vs -0.1% NCT03467932
- -0.9% vs -0.1% NCT03467932
- -0.5% vs -0.1% NCT03467932
- 0% vs 0.2% NCT02496000
- -0.0% vs 0.2% NCT02496000
Body weight, change (kg)
- Afrezza
- —Not posted · NCT00539890
- ORMD-0801
- —Trial running · NCT06731075
HbA1c below 7%
- Afrezza
- —Not posted · NCT00539890
- ORMD-0801
- —Trial running · NCT06731075
Fasting plasma glucose, change
- Afrezza
- —Not posted · NCT00539890
- ORMD-0801
- —Trial running · NCT06731075
3-point MACE (% with event)
- Afrezza
- —Not posted · NCT00539890
- ORMD-0801
- —Trial running · NCT06731075
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Afrezza: 4 of 4 rows · ORMD-0801: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Afrezza | ORMD-0801 |
|---|---|---|
| Dropout rate | 32%TI Inhalation Powder + Metformina NCT00332488 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 6 more results27.3%TI Inhalation Powder Alone NCT00332488 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Dose 1 NCT04849845 · Phase 4 · registry result, not featured evidence —Dose 2 NCT04849845 · Phase 4 · registry result, not featured evidence 0% NCT03324776 · Phase 3 · registry result, not featured evidence —60 U NCT00570687 · Phase 2 · registry result, not featured evidence —90 U NCT00570687 · Phase 2 · registry result, not featured evidence | —16 mg Once Daily (QD)b NCT03467932 · Phase 2 show 19 more results11.1%16 mg Once Daily (QHS) NCT03467932 · Phase 2 11.8%8 mg Twice Daily (BID) NCT03467932 · Phase 2 —8 mg Once Daily (QD) NCT03467932 · Phase 2 13.3%8 mg Once Daily (QHS) NCT03467932 · Phase 2 26.7%16 mg Twice Daily (BID) NCT03467932 · Phase 2 —Once Daily (QD) NCT03467932 · Phase 2 10.1%Once Daily (QHS) NCT03467932 · Phase 2 15.9%Three Times Daily (TID) NCT03467932 · Phase 2 14.7%Twice Daily (BID) NCT03467932 · Phase 2 0%QD NCT04616014 · Phase 2 · registry result, not featured evidence 9.5%8 mg BD NCT04618744 · Phase 2 · registry result, not featured evidence 16.7% NCT04564846 · Phase 2 · registry result, not featured evidence —Dose 1 NCT02954601 · Phase 2 · registry result, not featured evidence —Dose 2 NCT02954601 · Phase 2 · registry result, not featured evidence 0%Dose 3 NCT02954601 · Phase 2 · registry result, not featured evidence 8.2%Dose 1 NCT02496000 · Phase 2 · registry result, not featured evidence 3.2%1.5 * Dose 1 NCT02496000 · Phase 2 · registry result, not featured evidence 0%ORMD-0801 Dose # 1 NCT01889667 · Phase 2 · registry result, not featured evidence 0%ORMD-0801 Dose # 2 NCT01889667 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.4%TI Inhalation Powder + Metformina NCT00332488 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 6 more results4.4%TI Inhalation Powder Alone NCT00332488 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Dose 1 NCT04849845 · Phase 4 · registry result, not featured evidence —Dose 2 NCT04849845 · Phase 4 · registry result, not featured evidence — NCT03324776 · Phase 3 · registry result, not featured evidence —60 U NCT00570687 · Phase 2 · registry result, not featured evidence —90 U NCT00570687 · Phase 2 · registry result, not featured evidence | —16 mg Once Daily (QD)b NCT03467932 · Phase 2 show 19 more results—16 mg Once Daily (QHS) NCT03467932 · Phase 2 —8 mg Twice Daily (BID) NCT03467932 · Phase 2 —8 mg Once Daily (QD) NCT03467932 · Phase 2 —8 mg Once Daily (QHS) NCT03467932 · Phase 2 —16 mg Twice Daily (BID) NCT03467932 · Phase 2 —Once Daily (QD) NCT03467932 · Phase 2 —Once Daily (QHS) NCT03467932 · Phase 2 —Three Times Daily (TID) NCT03467932 · Phase 2 —Twice Daily (BID) NCT03467932 · Phase 2 —QD NCT04616014 · Phase 2 · registry result, not featured evidence 4.8%8 mg BD NCT04618744 · Phase 2 · registry result, not featured evidence — NCT04564846 · Phase 2 · registry result, not featured evidence —Dose 1 NCT02954601 · Phase 2 · registry result, not featured evidence —Dose 2 NCT02954601 · Phase 2 · registry result, not featured evidence —Dose 3 NCT02954601 · Phase 2 · registry result, not featured evidence —Dose 1 NCT02496000 · Phase 2 · registry result, not featured evidence —1.5 * Dose 1 NCT02496000 · Phase 2 · registry result, not featured evidence —ORMD-0801 Dose # 1 NCT01889667 · Phase 2 · registry result, not featured evidence —ORMD-0801 Dose # 2 NCT01889667 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 3.1%TI Inhalation Powder + Metformina NCT00332488 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 6 more results2.8%TI Inhalation Powder Alone NCT00332488 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0%Dose 1 NCT04849845 · Phase 4 · registry result, not featured evidence 0%Dose 2 NCT04849845 · Phase 4 · registry result, not featured evidence 0% NCT03324776 · Phase 3 · registry result, not featured evidence 0%60 U NCT00570687 · Phase 2 · registry result, not featured evidence 0%90 U NCT00570687 · Phase 2 · registry result, not featured evidence | 0%16 mg Once Daily (QD)b NCT03467932 · Phase 2 show 19 more results—16 mg Once Daily (QHS) NCT03467932 · Phase 2 0%8 mg Twice Daily (BID) NCT03467932 · Phase 2 0%8 mg Once Daily (QD) NCT03467932 · Phase 2 —8 mg Once Daily (QHS) NCT03467932 · Phase 2 6.7%16 mg Twice Daily (BID) NCT03467932 · Phase 2 7.2%Once Daily (QD) NCT03467932 · Phase 2 —Once Daily (QHS) NCT03467932 · Phase 2 4.3%Three Times Daily (TID) NCT03467932 · Phase 2 0%Twice Daily (BID) NCT03467932 · Phase 2 0%QD NCT04616014 · Phase 2 · registry result, not featured evidence 4.8%8 mg BD NCT04618744 · Phase 2 · registry result, not featured evidence 0% NCT04564846 · Phase 2 · registry result, not featured evidence 0%Dose 1 NCT02954601 · Phase 2 · registry result, not featured evidence 0%Dose 2 NCT02954601 · Phase 2 · registry result, not featured evidence 0%Dose 3 NCT02954601 · Phase 2 · registry result, not featured evidence 1.6%Dose 1 NCT02496000 · Phase 2 · registry result, not featured evidence 0%1.5 * Dose 1 NCT02496000 · Phase 2 · registry result, not featured evidence 0%ORMD-0801 Dose # 1 NCT01889667 · Phase 2 · registry result, not featured evidence 0%ORMD-0801 Dose # 2 NCT01889667 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a hypoglycaemia 23.9% cough 17.7% nasopharyngitis 5.1% NCT00332488 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 5 more resultscough 27.1% hypoglycaemia 13.3% upper respiratory tract infection 3.9% NCT00332488 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 60 U cough 66.7% phlebitis 16.7% acute sinusitis 0% NCT00570687 · Phase 2 · registry result, not featured evidence 90 U cough 83.3% nasopharyngitis 16.7% acute sinusitis 0% NCT00570687 · Phase 2 · registry result, not featured evidence | 16 mg Once Daily (QD)b anemia 5.6% (placebo 0%) abdominal discomfort 0% (placebo 1.2%) abdominal pain upper 0% (placebo 0%) NCT03467932 · Phase 2 show 14 more results8 mg Twice Daily (BID) anemia 5.9% (placebo 0%) cystitis 5.9% (placebo 1.2%) abdominal discomfort 0% (placebo 1.2%) NCT03467932 · Phase 2 8 mg Once Daily (QD) constipation 6.7% (placebo 0%) cystitis 6.7% (placebo 1.2%) diarrhoea 6.7% (placebo 3.7%) NCT03467932 · Phase 2 16 mg Twice Daily (BID) diverticulitis 6.7% (placebo 0%) nausea 6.7% (placebo 1.2%) abdominal discomfort 0% (placebo 1.2%) NCT03467932 · Phase 2 Once Daily (QD) anemia 4.3% (placebo 0%) atrial fibrillation 4.3% (placebo 0%) diarrhoea 2.9% (placebo 3.7%) NCT03467932 · Phase 2 Three Times Daily (TID) diarrhoea 11.6% (placebo 3.7%) nausea 1.4% (placebo 1.2%) seasonal allergy 1.4% (placebo 1.2%) NCT03467932 · Phase 2 Twice Daily (BID) diarrhoea 4.4% (placebo 3.7%) anemia 1.5% (placebo 0%) atrial fibrillation 1.5% (placebo 0%) NCT03467932 · Phase 2 QD diarrhia 57.1% steatorrhea 28.6% bronchitis 14.3% NCT04616014 · Phase 2 · registry result, not featured evidence 8 mg BD addominal distention 23.8% (placebo 0%) nausea 9.5% (placebo 0%) atrial fibrillation 4.8% (placebo 9.1%) NCT04618744 · Phase 2 · registry result, not featured evidence gastrointestinal disorders 12.5% (placebo 0%) headache 12.5% (placebo 8%) abdominal pain 4.2% (placebo 0%) NCT04564846 · Phase 2 · registry result, not featured evidence metabolism and nutrional disorders 25% (placebo 22.6%) gastrointestinal disorders 5% (placebo 9.7%) hypoglycemia 5% (placebo 6.5%) NCT02954601 · Phase 2 · registry result, not featured evidence metabolism and nutrional disorders 28.6% (placebo 22.6%) hypoglycemia 19% (placebo 6.5%) gastrointestinal disorders 9.5% (placebo 9.7%) NCT02954601 · Phase 2 · registry result, not featured evidence metabolism and nutrional disorders 10% (placebo 22.6%) eye disorders 5% (placebo 0%) hypoglycemia 5% (placebo 6.5%) NCT02954601 · Phase 2 · registry result, not featured evidence number 30% (placebo 50%) NCT01889667 · Phase 2 · registry result, not featured evidence number 40% (placebo 50%) NCT01889667 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 5 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Afrezza
show 1 more result
show 1 more result
ORMD-0801
show 13 more results
show 7 more results
show 5 more results
show 1 more result
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afrezza's landscape · ORMD-0801's landscape